We have observed
4 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after April 26, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
A mixture of polar glycolipids for use in the treatment of pain and COPD
CHO expression system
MODULATION OF RNA ACTIVITY AND VASCULAR PERMEABILITY
ROBO1-FC FUSION PROTEIN FOR USE IN THE TREATMENT OF HEPATOCARCINOMA